Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMB58 (flurpiridaz 18F) PET myocardial perfusion imaging in suspected ischemic heart disease
jRCT2080225119Phase 2Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Mar 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of Flurpiridaz F 18 in coronary arteriosclerosis, sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoints: Diagnostic sensitivity of NMB58 PET myocardial perfusion imaging, Diagnostic specificity of NMB58 PET myocardial perfusion imaging and 1 more. Started Mar 2020; status: completed.
02
Drugs
Flurpiridaz F 18
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on jRCT2080225119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225119.